PRQR Stock Overview
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ProQR Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.20 |
| 52 Week High | US$3.29 |
| 52 Week Low | US$1.11 |
| Beta | 0.25 |
| 1 Month Change | -14.06% |
| 3 Month Change | -12.00% |
| 1 Year Change | -5.17% |
| 3 Year Change | -62.59% |
| 5 Year Change | -80.60% |
| Change since IPO | -85.06% |
Recent News & Updates
Recent updates
Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Apr 03
Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?
Nov 28Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Jul 30Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt
Mar 17ProQR says EU regulator seeks additional trial for lead candidate
Aug 11Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money
Nov 10Investment Case On ProQR Therapeutics Gets More Enticing
Oct 01ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Aug 04ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data
Jun 20It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year
May 13ProQR Therapeutics offers a de-risked opportunity: Stifel
May 03If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%
Mar 08Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?
Feb 01
ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder
Jan 07ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Dec 28A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns
Dec 01ProQR reports Q3 results
Nov 16Shareholder Returns
| PRQR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.3% | -2.8% | -1.7% |
| 1Y | -5.2% | -0.2% | 22.4% |
Return vs Industry: PRQR underperformed the US Biotechs industry which returned -0.2% over the past year.
Return vs Market: PRQR underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| PRQR volatility | |
|---|---|
| PRQR Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PRQR's share price has been volatile over the past 3 months.
Volatility Over Time: PRQR's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 157 | Daniel de Boer | www.proqr.com |
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company’s products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets.
ProQR Therapeutics N.V. Fundamentals Summary
| PRQR fundamental statistics | |
|---|---|
| Market cap | US$178.98m |
| Earnings (TTM) | -US$29.92m |
| Revenue (TTM) | US$7.02m |
25.5x
P/S Ratio-6.0x
P/E RatioIs PRQR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRQR income statement (TTM) | |
|---|---|
| Revenue | €6.59m |
| Cost of Revenue | €0 |
| Gross Profit | €6.59m |
| Other Expenses | €34.71m |
| Earnings | -€28.12m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 100.00% |
| Net Profit Margin | -426.43% |
| Debt/Equity Ratio | 10.4% |
How did PRQR perform over the long term?
See historical performance and comparison